# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071563
Filing Date
2025-05-14
Accepted
2025-05-14 16:51:05
Documents
80
Period of Report
2025-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | aktx-20250331.htm iXBRL | 10-Q | 2103269
2 | EX-10.5 | aktx-ex10_5.htm | EX-10.5 | 110481
3 | EX-31.1 | aktx-ex31_1.htm | EX-31.1 | 15720
4 | EX-31.2 | aktx-ex31_2.htm | EX-31.2 | 15708
5 | EX-32.1 | aktx-ex32_1.htm | EX-32.1 | 11846
6 | EX-32.2 | aktx-ex32_2.htm | EX-32.2 | 11369
| Complete submission text file | 0000950170-25-071563.txt |  | 10672402

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | aktx-20250331.xsd | EX-101.SCH | 1821772
83 | EXTRACTED XBRL INSTANCE DOCUMENT | aktx-20250331_htm.xml | XML | 1927504

Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 10-Q | Act: 34 | File No.: 001-36288 | Film No.: 25946704
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)